← All indications
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
Subtype terms (2)
More specific conditions that are subtypes of Pneumococcal Infections in the MeSH hierarchy.
- Meningitis, Pneumococcal
2 drugs approved
- Pneumonia, Pneumococcal
25 drugs (14 approved, 11 experimental)
Drugs by status
Approved for this indication (13)
- 23-valent pneumococcal polysaccharide vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 7-valent conjugate vaccine
- phenoxymethylpenicillin
- anti-pneumococcal serum (equine)
- hexavalent pneumococcal polysaccharide vaccine
- serotype 1 pneumococcal polysaccharide antigen ('felton antigen')
- serotype-specific whole-cell pneumococcal vaccines
- streptococcal vaccine - polysacchararide 14-valent
- lincomycin
- 15-valent pneumococcal conjugate vaccine
- 20-valent pneumococcal conjugate vaccine
- Pneumococcal 21-valent conjugate vaccine
Phase 4 trials (16)
- levofloxacin
- immunovac
- menitorix
- menjugate
- tivantinib
- multi-valent pneumococcal conjugate vaccine
- inactivated influenza vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- diphtheria toxoid
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- tetanus toxoid
- Azoximer
- vi-dt typhoid conjugate vaccine
- neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
- spn3
- Monovalent group C meningococcal vaccine
Phase 3 trials (17)
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- hepatitis b vaccine (recombinant)
- rotavirus vaccine, live, oral, pentavalent
- hepatitis a vaccine, inactivated
- inactivated poliovirus type 2 vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- live attenuated varicella vaccine
- measles, mumps, and rubella vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- bivalent oral polio vaccine (bopv), type 1 and type 3
- human rotavirus, live attenuated
- mrna-1273
- bnt162b2
- v110
Phase 2 trials (9)
Phase 1 trials (12)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (32)
- Merck
- Pfizer
- Wyeth
- Novartis
- National Institutes of Health (NIH)
- Public Health England
- Agence de Médecine Préventive, France
- Centre Muraz
- University of London
- Korea University
- Minsk State Clinical Hospital No 9
- Russian Academy of Medical Sciences
- University of Liverpool
- University of Bristol
- Health Protection Agency, United Kingdom
- Belarusian State Medical University
- University of Indonesia
- Institute of Sera and Vaccines RAS, Moscow
- University of Malawi
- National Taiwan University
- University of Oxford
- Royal Liverpool & Broadgreen University Hospitals NHS Truts
- Friedrich Schiller University
- Government of China
- Wellcome Trust
- Moorgreen Hospital, Southampton
- Department of Veteran Affairs
- Department of Health, United Kingdom
- China National Biotec Group Co., Ltd
- Bill and Melinda Gates Foundation
- +2 more
Organization Involved with Phase 3 Indications (24)
- Sanofi-Aventis
- GlaxoSmithKline
- Sinovac Biotech Co., Ltd
- Walvax Biotechnology Co., Ltd.
- Menzies School of Health Research
- Seoul National University
- University of Melbourne
- University of Siena
- University of Sydney
- Utrecht University
- Dalhousie University
- University of British Columbia
- University of Calgary
- University of Montreal
- SK Chemicals
- National Health and Medical Research Council, Australia
- Canadian Institutes of Health Research (CIHR)
- Canadian Immunization Research Network
- Government of Finland
- Mason Medical Research Trust
- Netherlands Vaccine Institute
- Government of Italy
- Government of Netherlands
- People's Liberation Army of China
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (17)
- Valneva
- Sanofi
- Combioxin SA
- National Institute on Aging (NIA)
- Emory University
- University of Maryland
- Stony Brook University
- University of Limoges
- ImmunoBiology Ltd
- University of Toledo
- Alaska Native Tribal Health Consortium
- ORION Clinical Services
- Tianjin Cansino Biotechnology Inc
- Oxford Therapeutics Consulting Limited
- Southcentral Foundation
- Centers for Disease Control and Prevention (CDC)
- Simbec-Orion
Organization Involved with Other Experimental Indications (3)